3.61

3.74% -0.13

Cardiff Oncology Inc (CRDF)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Cardiff Oncology Inc stock is traded at $3.61, with a volume of 629.42K. It is down -3.74% in the last 24 hours and up +38.46% over the past month. Cardiff Oncology Inc a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC").

Previous Close:

$3.74

Open:

$3.78

24h Volume:

629.42K

Relative Volume:

1.11

Market Cap:

$174.10M

Revenue:

$488.00K

Net Income/Loss:

$-41.44M

P/E Ratio:

-4.0111

EPS:

-0.9

Net Cash Flow:

$-31.47M

1W Performance:

+15.38%

1M Performance:

+38.46%

6M Performance:

+2.27%

1Y Performance:

+224.32%

1-Day Range:

$3.50

$3.8184

1-Week Range:

$3.00

$3.8184

52-Week Range:

$0.94

$6.42

Cardiff Oncology Inc Stock (CRDF) Company Profile

Name

Cardiff Oncology Inc

Sector

Healthcare (1181)

Industry

Biotechnology (680)

Phone

858-952-7570

Address

11055 FLINTKOTE AVENUE, SAN DIEGO, CA

Employee

Twitter

@cardiffoncology

Next Earnings Date

2024-10-31

Latest SEC Filings

CRDF's Discussions on Twitter

Cardiff Oncology Inc Stock (CRDF) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-05-22	Initiated	William Blair	Outperform
Dec-08-21	Initiated	Robert W. Baird	Outperform
Aug-09-21	Resumed	Maxim Group	Buy
Oct-22-20	Initiated	H.C. Wainwright	Buy
Oct-08-20	Initiated	Piper Sandler	Overweight

Cardiff Oncology Inc Stock (CRDF) Latest News

Nov 03, 2024

Cardiff Oncology, Inc. (NASDAQ:CRDF) Shares Sold by Assenagon Asset Management S.A. - MarketBeat

Nov 03, 2024

Nov 02, 2024

Cardiff Oncology (FRA:XE7C) Float Percentage Of Total Shares Outstanding : 97.27% (As of Nov. 02, 2024) - GuruFocus.com

Nov 02, 2024

Nov 01, 2024

Cardiff Oncology, Inc. (NASDAQ:CRDF) Short Interest Up 7.2% in October - MarketBeat

Nov 01, 2024

Oct 30, 2024

Cardiff Oncology Announces Journal of Clinical Oncology - GlobeNewswire

Oct 30, 2024

Cardiff Oncology Announces Journal of Clinical Oncology Publication of Data from Phase 2 Trial in Second-line KRAS Mutant mCRC - StockTitan

Oct 30, 2024

Oct 29, 2024

Alley Investment Management Company LLC Purchases New Stake in NVIDIA Co. (NASDAQ:NVDA) - Defense World

Oct 29, 2024

Oct 25, 2024

NA Liquid Biopsy Market 2024 To Witness Amazing Growth By 2032 - openPR

Oct 25, 2024

Oct 24, 2024

3 US Penny Stocks With Market Caps Over $40M - Simply Wall St

Oct 24, 2024

Oct 22, 2024

JAK Inhibitors Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 50+ Companies Working in the Domain - The Malaysian Reserve

Oct 22, 2024

Oct 15, 2024

KRAS Inhibitors Market Poised to Reach $157.6 Million by 2031, Driven by 5.61% CAGR As Revealed In New Report - WhaTech

Oct 15, 2024

Oct 14, 2024

Will Cardiff Oncology's Onvansertib Data Boost Its Stock Price? - RTTNews

Oct 14, 2024

Oct 10, 2024

Metastatic Castration-Resistant Prostate Cancer Clinical Trial Pipeline Appears Robust With 90+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Malaysian Reserve

Oct 10, 2024

Cardiff Oncology Inc’s: Contrasting Stock Performances in a Volatile Market - The InvestChronicle

Oct 10, 2024

Oct 09, 2024